Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 4
Submit an article Journal homepage
410
Views
7
CrossRef citations to date
0
Altmetric
Original Articles

Life-threatening complications after high-dose methotrexate and the benefits of glucarpidase as salvage therapy: a cohort study of 468 patients

Chloé Medranoa Département de Néphrologie et Transplantation d’organes – Unité de Réanimation, Centre Hospitalier Universitaire de Toulouse, French Intensive Care Renal Network, Toulouse, France
,
Lucie Obericb Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
,
Florent Puissetc Laboratoire de Pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, and Centre de Recherche sur la Cancer de Toulouse, INSERM UMR-1037, Toulouse, France
,
Christian Recherb Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
,
Delphine Larrieu-Cirond Service de Neurologie, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
,
Loïc Ysebaertb Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
,
Caroline Protinb Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
,
Muriel Picarde Département d’anesthésie et de réanimation, Réanimation Médicale, Institut Universitaire du Cancer de Toulouse – Oncopole, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
,
Sophie Perriatc Laboratoire de Pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, and Centre de Recherche sur la Cancer de Toulouse, INSERM UMR-1037, Toulouse, France
,
Etienne Chatelutc Laboratoire de Pharmacologie, Institut Claudius-Regaud, Institut Universitaire du Cancer de Toulouse - Oncopôle, and Centre de Recherche sur la Cancer de Toulouse, INSERM UMR-1037, Toulouse, FranceORCID Iconhttps://orcid.org/0000-0002-7740-9096
ORCID Icon,
Sarah Bertolib Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
,
Françoise Huguetb Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
,
Suzanne Tavitianb Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse – Oncopôle, Université Toulouse III Paul Sabatier, Toulouse, France
&
Stanislas Faguera Département de Néphrologie et Transplantation d’organes – Unité de Réanimation, Centre Hospitalier Universitaire de Toulouse, French Intensive Care Renal Network, Toulouse, France;f INSERM U1048 (Institut des Maladies Métaboliques et Cardiovasculaires, équipe 12), Hôpital Rangueil, Toulouse, France;g Université Paul Sabatier – Toulouse III, Toulouse, FranceCorrespondence[email protected]
 show all
Pages 846-853 | Received 25 Apr 2020, Accepted 26 Oct 2020, Published online: 12 Nov 2020

References

  • Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol. 2009;146(5):489–503.
  • Howard SC, McCormick J, Pui C, et al. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482.
  • Holmboe L, Andersen AM, Mørkrid L, et al. High dose methotrexate chemotherapy: Pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol. 2012;73(1):106–114.
  • Maiguma T, Hayashi Y, Ueshima S, et al. Relationship between oral mucositis and high-dose methotrexate therapy in pediatric acute lymphoblastic leukemia. Int J Clin Pharmacol Ther. 2008;46(11):584–590.
  • Dabagh S, David H, Young S, et al. Severe, fatal methotrexate-related neurotoxicity in 2 adolescent patients with ALL. J Pediat Hematol Oncol. 2019;42:e839–e844.
  • Widemann BC, Balis FM, Kempf-Bielack B, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma: incidence, treatment, and outcome. Cancer. 2004;100(10):2222–2232.
  • Green MR, Chamberlain MC. Renal dysfunction during and after high-dose methotrexate. Cancer Chemother Pharmacol. 2009;63(4):599–604.
  • Hoang-Xuan K, Taillandier L, Chinot O, et al. European Organization for Research and Treatment of Cancer Brain Tumor Group. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol. 2003;21(14):2726–2731.
  • Wiczer T, Dotson E, Tuten A, et al. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity. J Oncol Pharm Pract. 2016;22(3):430–436.
  • Ramsey LB, Balis FM, O'Brien MM, et al. Consensus guideline for use of glucarpidase in patients with high-dose methotrexate induced acute kidney injury and delayed methotrexate clearance . Oncologist. 2018;23(1):52–61.
  • Schwartz S, Borner K, Müller K, et al. Glucarpidase (carboxypeptidase g2) intervention in adult and elderly cancer patients with renal dysfunction and delayed methotrexate elimination after high-dose methotrexate therapy. Oncologist. 2007;12(11):1299–1308.
  • Kellum JA, Lameire N. KDIGO AKI Guideline Work Group. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care. 2013;17(1):204.
  • Heuser M, Ofran Y, Boissel N, et al.; ESMO Guidelines Committee. Acute myeloid leukemia in adult patients: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(6):697–712.
  • Mikkelsen TS, Mamoudou AD, Tuckuviene R, et al. Extended duration of prehydration does not prevent nephrotoxicity or delayed drug elimination in high-dose methotrexate infusions: A prospectively randomized cross-over study. Pediatr Blood Cancer. 2014;61(2):297–301.
  • Liu KD, Yang J, Tan TC, et al. Risk factors for recurrent acute kidney injury in a large population-based cohort. Am J Kidney Dis. 2019;73(2):163–173.
  • Canaud G, Bonventre JV. Cell cycle arrest and the evolution of chronic kidney disease from acute kidney injury. Nephrol Dialysis Transpl. 2015;30(4):575–583.
  • Garneau AP, Riopel J, Isenring P. Acute methotrexate-induced crystal nephropathy. N Engl J Med. 2015;373(27):2691–2693.
  • Grönroos M, Chen M, Jahnukainen T, et al. Methotrexate induces cell swelling and necrosis in renal tubular cells. Pediatr Blood Cancer. 2006;46:624–629.
  • Radtke S, Zolk O, Renner B, et al. Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. Blood. 2013;121(26):5145–5153.
  • Widemann BC, Schwartz S, Jayaprakash N, et al. Efficacy of glucarpidase (carboxypeptidase G2) in patients with acute kidney injury after high-dose methotrexate therapy. Pharmacotherapy. 2014;34(5):427–439.
  • Boelens AD, Mathôt RAA, Vlaar APJ, et al. Glucarpidase treatment for methotrexate intoxication: a case report and review of the literature. Neth J Med. 2018;76(1):36–39.
  • Wyatt KD, Cooper J, Scott K, et al. Delayed methotrexate clearance despite carboxypeptidase-g2 (glucarpidase) administration in 2 patients with toxic methotrexate levels. J Pediat Hematol Oncol. 2018;40:152–155.
  • Demiralp B, Koenig L, Kala J, et al. Length of stay, mortality, and readmissions among Medicare cancer patients treated with glucarpidase and conventional care: a retrospective study. Clinicoecon Outcomes Res. 2019;11:129–144.
  • Fermiano M, Bergsbaken J, Kolesar JM. Glucarpidase for the management of elevated methotrexate levels in patients with impaired renal function. Am J Health Syst Pharm. 2014;71(10):793–798.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.